From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario

Author(s): Marco Rossi, Nicola Amodio, Maria Teresa Di Martino, Daniele Caracciolo, Pierosandro Tagliaferri, Pierfrancesco Tassone

Journal Name: Current Drug Targets

Volume 14 , Issue 10 , 2013

Become EABM
Become Reviewer
Call for Editor


The progress in the understanding of biological events underlying multiple myeloma (MM) development and progression has allowed the design of molecularly targeted therapies (MTTs) for this disease and several new compounds are presently under investigation in the preclinical and clinical settings. The recent discovery that miRNAs, and short non coding RNAs in general, are involved in the pathogenesis of cancer has raised the issue whether a novel therapeutic approach should be provided by selective interference with miRNA network. This review will focus on the rationale of miRNA-based therapeutics, providing the most relevant information on biogenesis and technical issues in miRNA analysis. Finally, a detailed overview of the recent findings on miRNA therapeutics of MM will be discussed.

Keywords: Bone disease, microRNA, miRNA, multiple myeloma, non coding RNA, target therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 June, 2013
Page: [1144 - 1149]
Pages: 6
DOI: 10.2174/13894501113149990186
Price: $65

Article Metrics

PDF: 18